An Open-Label Administration of Bioavailable-Form Curcumin in Patients With Pelizaeus-Merzbacher Disease
Copyright © 2023 Elsevier Inc. All rights reserved..
BACKGROUND: Two preclinical studies using mouse models of Pelizeaus-Merzbacher disease (PMD) have revealed the potential therapeutic effects of curcumin. In this study, we examined the effects of curcumin in patients with PMD.
METHODS: We conducted a study administering an open-label oral bioavailable form of curcumin in nine patients genetically confirmed to have PMD (five to 20 years; mean 11 years) for 12 months (low doses for two months followed by high doses for 10 months). We evaluated changes in clinical symptoms as the primary end point using two scales, Gross Motor Function Measure (GMFM) and the PMD Functional Disability Score (PMD-FDS). The level of myelination by brain magnetic resonance imaging (MRI) and the electrophysiological state by auditory brainstem response (ABR) were evaluated as secondary end points. The safety and tolerability of oral curcumin were also examined.
RESULTS: Increase in GMFM and PMD-FDS were noted in five and three patients, respectively, but overall, no statistically significant improvement was demonstrated. We found no clear improvement in their brain MRI or ABR. No adverse events associated with oral administration of curcumin were observed.
CONCLUSIONS: Although we failed to demonstrate any significant therapeutic effects of curcumin after 12 months, its tolerability and safety were confirmed. This study does not exclude the possibility of therapeutic effects of curcumin, and a trial of longer duration should be considered to compare the natural history of the disease with the effects of curcumin.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:151 |
|---|---|
| Enthalten in: |
Pediatric neurology - 151(2024) vom: 05. Jan., Seite 80-83 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yamamoto, Akiyo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Curcumin |
|---|
| Anmerkungen: |
Date Completed 15.01.2024 Date Revised 15.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pediatrneurol.2023.11.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36625524X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36625524X | ||
| 003 | DE-627 | ||
| 005 | 20240115232002.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pediatrneurol.2023.11.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1260.xml |
| 035 | |a (DE-627)NLM36625524X | ||
| 035 | |a (NLM)38134864 | ||
| 035 | |a (PII)S0887-8994(23)00414-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yamamoto, Akiyo |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An Open-Label Administration of Bioavailable-Form Curcumin in Patients With Pelizaeus-Merzbacher Disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2024 | ||
| 500 | |a Date Revised 15.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Two preclinical studies using mouse models of Pelizeaus-Merzbacher disease (PMD) have revealed the potential therapeutic effects of curcumin. In this study, we examined the effects of curcumin in patients with PMD | ||
| 520 | |a METHODS: We conducted a study administering an open-label oral bioavailable form of curcumin in nine patients genetically confirmed to have PMD (five to 20 years; mean 11 years) for 12 months (low doses for two months followed by high doses for 10 months). We evaluated changes in clinical symptoms as the primary end point using two scales, Gross Motor Function Measure (GMFM) and the PMD Functional Disability Score (PMD-FDS). The level of myelination by brain magnetic resonance imaging (MRI) and the electrophysiological state by auditory brainstem response (ABR) were evaluated as secondary end points. The safety and tolerability of oral curcumin were also examined | ||
| 520 | |a RESULTS: Increase in GMFM and PMD-FDS were noted in five and three patients, respectively, but overall, no statistically significant improvement was demonstrated. We found no clear improvement in their brain MRI or ABR. No adverse events associated with oral administration of curcumin were observed | ||
| 520 | |a CONCLUSIONS: Although we failed to demonstrate any significant therapeutic effects of curcumin after 12 months, its tolerability and safety were confirmed. This study does not exclude the possibility of therapeutic effects of curcumin, and a trial of longer duration should be considered to compare the natural history of the disease with the effects of curcumin | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Curcumin | |
| 650 | 4 | |a Hypomyelinating leukodystrophy | |
| 650 | 4 | |a Pelizaeus-Merzbacher disease | |
| 650 | 4 | |a Treatment | |
| 650 | 7 | |a Curcumin |2 NLM | |
| 650 | 7 | |a IT942ZTH98 |2 NLM | |
| 650 | 7 | |a Myelin Proteolipid Protein |2 NLM | |
| 700 | 1 | |a Shimizu-Motohashi, Yuko |e verfasserin |4 aut | |
| 700 | 1 | |a Ishiyama, Akihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kurosawa, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Sasaki, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Noriko |e verfasserin |4 aut | |
| 700 | 1 | |a Osaka, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Takanashi, Jun-Ichi |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Ken |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric neurology |d 1993 |g 151(2024) vom: 05. Jan., Seite 80-83 |w (DE-627)NLM012947210 |x 1873-5150 |7 nnns |
| 773 | 1 | 8 | |g volume:151 |g year:2024 |g day:05 |g month:01 |g pages:80-83 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pediatrneurol.2023.11.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 151 |j 2024 |b 05 |c 01 |h 80-83 | ||